Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 192 articles:
HTML format



Single Articles


    April 2021
  1. HERSCH J, Barratt A, McGeechan K, Jansen J, et al
    Informing Women About Overdetection in Breast Cancer Screening: Two-year Outcomes from a Randomized Trial.
    J Natl Cancer Inst. 2021 Apr 19. pii: 6237906. doi: 10.1093.
    PubMed     Abstract available


  2. FEIGELSON HS, Bodelon C, Powers JD, Curtis RE, et al
    Body Mass Index and Risk of Second Cancer among Women with Breast Cancer.
    J Natl Cancer Inst. 2021 Apr 5. pii: 6210655. doi: 10.1093.
    PubMed     Abstract available


  3. DEKKER J, Stege CAM, Versteeg KS
    Re: Deficit Accumulation Frailty Trajectories of Older Breast Cancer Survivors and Non-Cancer Controls: The Thinking and Living with Cancer Study.
    J Natl Cancer Inst. 2021 Apr 5. pii: 6210765. doi: 10.1093.
    PubMed    


  4. RICHMAN IB, Long JB, Hoag JR, Upneja A, et al
    Comparative Effectiveness of Digital Breast Tomosynthesis for Breast Cancer Screening among Women 40-64 Years Old.
    J Natl Cancer Inst. 2021 Apr 3. pii: 6209735. doi: 10.1093.
    PubMed     Abstract available


  5. YU KD, Ge JY, Liu XY, Mo M, et al
    Cyclophosphamide-free Adjuvant Chemotherapy for Ovarian Protection in Young Women with Breast Cancer: a Randomized Phase 3 Trial.
    J Natl Cancer Inst. 2021 Apr 2. pii: 6209077. doi: 10.1093.
    PubMed     Abstract available


  6. LAMBERTINI M, Partridge AH
    Cyclophosphamide-free Adjuvant Chemotherapy for the Potential Prevention of Premature Ovarian Insufficiency and Infertility in Young Women with Breast Cancer.
    J Natl Cancer Inst. 2021 Apr 2. pii: 6209078. doi: 10.1093.
    PubMed    


    March 2021
  7. POLLEY MC
    On the Quest of Risk Stratification in HER2-Positive Breast Cancer.
    J Natl Cancer Inst. 2021 Mar 31. pii: 6206391. doi: 10.1093.
    PubMed    


  8. CHIC N, Luen SJ, Nuciforo P, Salgado R, et al
    Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer.
    J Natl Cancer Inst. 2021 Mar 31. pii: 6206389. doi: 10.1093.
    PubMed     Abstract available


  9. PISANO ED, Gatsonis C, Sparano J, Troester MA, et al
    RE: Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium.
    J Natl Cancer Inst. 2021 Mar 30. pii: 6203812. doi: 10.1093.
    PubMed    


  10. REINER AS, Watt GP, John EM, Lynch CF, et al
    Smoking, Radiation Therapy, and Contralateral Breast Cancer Risk in Young Women.
    J Natl Cancer Inst. 2021 Mar 29. pii: 6199433. doi: 10.1093.
    PubMed     Abstract available


  11. DU Z, Gao G, Adedokun B, Ahearn T, et al
    Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry.
    J Natl Cancer Inst. 2021 Mar 26. pii: 6189099. doi: 10.1093.
    PubMed     Abstract available


  12. HOULAHAN KE
    Do Breast Cancer Risk Scores Work for You?
    J Natl Cancer Inst. 2021 Mar 25. pii: 6189097. doi: 10.1093.
    PubMed    


    February 2021
  13. LOHMANN AE, Soldera SV, Pimentel I, Ribnikar D, et al
    Association of Obesity with Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis.
    J Natl Cancer Inst. 2021 Feb 23. pii: 6147022. doi: 10.1093.
    PubMed     Abstract available


  14. EMENS LA, Molinero L, Loi S, Rugo HS, et al
    Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
    J Natl Cancer Inst. 2021 Feb 1. pii: 6125365. doi: 10.1093.
    PubMed     Abstract available


  15. LIM B
    PD-L1 in Breast Cancer: The oad to the erfect iomarker is raught with ncertainty.
    J Natl Cancer Inst. 2021 Feb 1. pii: 6125363. doi: 10.1093.
    PubMed    


    January 2021
  16. VAN RAVESTEYN NT, Schechter CB, Hampton JM, Alagoz O, et al
    Trade-Offs Between Harms and Benefits of Different Breast Cancer Screening Intervals Among Low-Risk Women.
    J Natl Cancer Inst. 2021 Jan 30. pii: 6124199. doi: 10.1093.
    PubMed     Abstract available


  17. PACE LE, Keating NL
    Should Women at Lower-Than-Average Risk of Breast Cancer Undergo Less Frequent Screening?
    J Natl Cancer Inst. 2021 Jan 30. pii: 6124198. doi: 10.1093.
    PubMed    


  18. TRAPANI D, Yves Douillard J, Winer EP, Burstein H, et al
    The global landscape of treatment standards for breast cancer.
    J Natl Cancer Inst. 2021 Jan 27. pii: 6120790. doi: 10.1093.
    PubMed     Abstract available


  19. MANDELBLATT JS, Zhou X, Small BJ, Ahn J, et al
    Deficit Accumulation Frailty Trajectories of Older Breast Cancer Survivors and Non-Cancer Controls: The Thinking and Living with Cancer Study.
    J Natl Cancer Inst. 2021 Jan 23. pii: 6117333. doi: 10.1093.
    PubMed     Abstract available


    December 2020
  20. ALABOUSI M, Wadera A, Kashif Al-Ghita M, Al-Ghetaa RK, et al
    Performance of Digital Breast Tomosynthesis, Synthetic Mammography and Digital Mammography in Breast Cancer Screening: A Systematic Review and Meta-Analysis.
    J Natl Cancer Inst. 2020 Dec 29. pii: 6054799. doi: 10.1093.
    PubMed     Abstract available


  21. BORDE J, Ernst C, Wappenschmidt B, Niederacher D, et al
    Performance of breast cancer polygenic risk scores in 760 female CHEK2 germline mutation carriers.
    J Natl Cancer Inst. 2020 Dec 29. pii: 6054801. doi: 10.1093.
    PubMed     Abstract available


  22. ELMORE JG, Lee CI
    Keeping Pace with Technology Advances in Breast Cancer Screening: Synthetic 2D Images Outperform Digital Mammography.
    J Natl Cancer Inst. 2020 Dec 29. pii: 6054798. doi: 10.1093.
    PubMed    


  23. REIS-FILHO JS, Davidson NE
    Ki67 Assessment in Breast Cancer: Are We There yet?
    J Natl Cancer Inst. 2020 Dec 28. pii: 6053793. doi: 10.1093.
    PubMed    


  24. NIELSEN TO, Leung SCY, Rimm DL, Dodson A, et al
    Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working Group.
    J Natl Cancer Inst. 2020 Dec 28. pii: 6053794. doi: 10.1093.
    PubMed     Abstract available


  25. RAKOVITCH E, Sutradhar R, Nofech-Mozes S, Gu S, et al
    21-Gene Assay and Breast Cancer Mortality in Ductal Carcinoma in Situ.
    J Natl Cancer Inst. 2020 Dec 28. pii: 6053792. doi: 10.1093.
    PubMed     Abstract available


  26. HOUGHTON SC, Eliassen H, Tamimi RM, Willett WC, et al
    Central adiposity and subsequent risk of breast cancer by menopause status.
    J Natl Cancer Inst. 2020 Dec 26. pii: 6050830. doi: 10.1093.
    PubMed     Abstract available


  27. CHECK DK, Winn AN, Fergestrom N, Reeder-Hayes KE, et al
    Response to Strassels and Durham.
    J Natl Cancer Inst. 2020;112:1280.
    PubMed    


  28. BLAES AH, Dang C
    Trastuzumab: Weighing the Benefits and the Risks.
    J Natl Cancer Inst. 2020;112:1181-1182.
    PubMed    


  29. MACINNIS RJ, Knight JA, Chung WK, Milne RL, et al
    Comparing Five-Year and Lifetime Risks of Breast Cancer in the Prospective Family Study Cohort.
    J Natl Cancer Inst. 2020 Dec 10. pii: 6029579. doi: 10.1093.
    PubMed     Abstract available


  30. ETZIONI R, Shen Y, Shih YT
    Identifying Preferred Breast Cancer Risk Predictors: A Holistic Perspective.
    J Natl Cancer Inst. 2020 Dec 10. pii: 6029577. doi: 10.1093.
    PubMed    


    November 2020
  31. KERLIKOWSKE K, Bissell MCS, Sprague BL, Buist DSM, et al
    Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium.
    J Natl Cancer Inst. 2020 Nov 10. pii: 5970482. doi: 10.1093.
    PubMed     Abstract available


  32. MA D, Chen SY, Ren JX, Pei YC, et al
    Molecular features and functional implications of germline variants in triple-negative breast cancer.
    J Natl Cancer Inst. 2020 Nov 5. pii: 5956725. doi: 10.1093.
    PubMed     Abstract available


  33. YADAV S, LaDuca H, Polley EC, Hu C, et al
    Racial and ethnic differences in multigene hereditary cancer panel test results for women with breast cancer.
    J Natl Cancer Inst. 2020 Nov 4. pii: 5955835. doi: 10.1093.
    PubMed     Abstract available


  34. COLDITZ GA, Toriola AT
    Refining the focus on early life and adolescent pathways to prevent breast cancer.
    J Natl Cancer Inst. 2020 Nov 2. pii: 5951178. doi: 10.1093.
    PubMed    


  35. HOFVIND S, Sebuodegard S, Botteri E
    Response to Zahl.
    J Natl Cancer Inst. 2020;112:1175.
    PubMed    


    October 2020
  36. SCHOORMANS D
    RE: Cardiovascular disease in breast cancer survivors: an important topic in breast cancer survivorship.
    J Natl Cancer Inst. 2020 Oct 15. pii: 5924374. doi: 10.1093.
    PubMed    


    September 2020
  37. DIGNAM JJ
    Disparities in Breast Cancer: Narrowing the Gap.
    J Natl Cancer Inst. 2020 Sep 28. pii: 5912531. doi: 10.1093.
    PubMed    


  38. ZAHL PH
    RE: Breast cancer mortality after implementation of organized population-based screening in Norway.
    J Natl Cancer Inst. 2020 Sep 28. pii: 5912532. doi: 10.1093.
    PubMed    


  39. ALBAIN KS, Gray RJ, Makower DF, Faghih A, et al
    Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial.
    J Natl Cancer Inst. 2020 Sep 28. pii: 5912534. doi: 10.1093.
    PubMed     Abstract available


  40. STRASSELS SA, Durham DD
    Re: Concurrent Opioid and Benzodiazepine Prescriptions Among Older Women Diagnosed With Breast Cancer.
    J Natl Cancer Inst. 2020 Sep 21. pii: 5909658. doi: 10.1093.
    PubMed    



  41. Correction: Genetic Factors, Adherence to Healthy Lifestyle Behavior, and Risk of Invasive Breast Cancer Among Women in the UK Biobank.
    J Natl Cancer Inst. 2020 Sep 15. pii: 5906112. doi: 10.1093.
    PubMed    


  42. JATOI I, Pinsky PF
    Breast Cancer Screening Trials: Endpoints and Over-diagnosis.
    J Natl Cancer Inst. 2020 Sep 8. pii: 5902831. doi: 10.1093.
    PubMed     Abstract available



  43. Corrigendum: Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
    J Natl Cancer Inst. 2020 Sep 3. pii: 5901262. doi: 10.1093.
    PubMed    


  44. HELZLSOUER KJ, Reedy J
    Data Sharing for the Public Good.
    J Natl Cancer Inst. 2020;112:867-868.
    PubMed    


    August 2020
  45. VAN DEN BROEK JJ, Schechter CB, van Ravesteyn NT, Janssens ACJW, et al
    Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History.
    J Natl Cancer Inst. 2020 Aug 27. pii: 5898201. doi: 10.1093.
    PubMed     Abstract available


  46. MAGUIRE S, Perraki E, Tomczyk K, Jones ME, et al
    Common susceptibility loci for male breast cancer.
    J Natl Cancer Inst. 2020 Aug 12. pii: 5885091. doi: 10.1093.
    PubMed     Abstract available


  47. MAGBANUA MJM, Hendrix LH, Hyslop T, Barry WT, et al
    Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy.
    J Natl Cancer Inst. 2020 Aug 8. pii: 5889954. doi: 10.1093.
    PubMed     Abstract available


  48. FRANZOI MA, Eiger D, Ameye L, Ponde N, et al
    Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy.
    J Natl Cancer Inst. 2020 Aug 4. pii: 5880554. doi: 10.1093.
    PubMed     Abstract available


  49. ANURAG M, Ellis MJ
    Response to Jezequel, Patsouris, Guette, et al.
    J Natl Cancer Inst. 2020;112:865.
    PubMed    


    July 2020
  50. RAMIN C, Schaeffer ML, Zheng Z, Connor AE, et al
    All-cause and cardiovascular disease mortality among breast cancer survivors in CLUE II, a long-standing community-based cohort.
    J Natl Cancer Inst. 2020 Jul 7. pii: 5868410. doi: 10.1093.
    PubMed     Abstract available


  51. BLAES AH, Konety SH
    Cardiovascular disease in breast cancer survivors: an important topic in breast cancer survivorship.
    J Natl Cancer Inst. 2020 Jul 7. pii: 5868411. doi: 10.1093.
    PubMed    


  52. FLORIS G, Richard F, Hamy AS, Jongen L, et al
    Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2020 Jul 6. pii: 5867914. doi: 10.1093.
    PubMed     Abstract available


  53. LOHMANN AE, Goodwin PJ
    Obesity and Breast Cancer: Expanding the Hypothesis Space.
    J Natl Cancer Inst. 2020 Jul 6. pii: 5867915. doi: 10.1093.
    PubMed    


  54. BENEFIELD HC, Allott EH, Reeder-Hayes KE, Perou CM, et al
    Borderline Estrogen Receptor-Positive Breast Cancers in Black and White Women.
    J Natl Cancer Inst. 2020;112:728-736.
    PubMed     Abstract available


    June 2020
  55. O'LEARY B, Cutts RJ, Huang X, Hrebien S, et al
    Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
    J Natl Cancer Inst. 2020 Jun 17. pii: 5858980. doi: 10.1093.
    PubMed     Abstract available


    May 2020
  56. FREEDMAN RA, Sedrak MS, Bellon JR, Block CC, et al
    Weathering the Storm: Managing Older Adults with Breast Cancer Amid COVID-19 and Beyond.
    J Natl Cancer Inst. 2020 May 25. pii: 5843796. doi: 10.1093.
    PubMed     Abstract available


  57. MCCARTHY AM, Armstrong K
    Genetic Testing May Help Reduce Breast Cancer Disparities for African American Women.
    J Natl Cancer Inst. 2020 May 19. pii: 5838710. doi: 10.1093.
    PubMed    


  58. PALMER JR, Polley EC, Hu C, John EM, et al
    Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women.
    J Natl Cancer Inst. 2020 May 19. pii: 5838706. doi: 10.1093.
    PubMed     Abstract available


  59. SCHETTINI F, Giudici F, Giuliano M, Cristofanilli M, et al
    Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis.
    J Natl Cancer Inst. 2020 May 14. pii: 5837114. doi: 10.1093.
    PubMed     Abstract available


  60. KAPOOR PM, Mavaddat N, Choudhury PP, Wilcox AN, et al
    Combined associations of a polygenic risk score and classical risk factors with breast cancer risk.
    J Natl Cancer Inst. 2020 May 2. pii: 5828224. doi: 10.1093.
    PubMed     Abstract available


  61. LIN CH, Yap YS, Lee KH, Yeo W, et al
    Response to Sung, Rosenberg, and Yang.
    J Natl Cancer Inst. 2020;112:547-548.
    PubMed    


    April 2020
  62. RUSHTON M, Lima I, Tuna M, Johnson C, et al
    Impact of stopping trastuzumab in early breast cancer: a population-based study in Ontario, Canada.
    J Natl Cancer Inst. 2020 Apr 28. pii: 5826355. doi: 10.1093.
    PubMed     Abstract available


  63. IZCI H, Tambuyzer T, Tuand K, Depoorter V, et al
    A Systematic Review of Estimating Breast Cancer Recurrence at the Population-Level with Administrative Data.
    J Natl Cancer Inst. 2020 Apr 7. pii: 5817318. doi: 10.1093.
    PubMed     Abstract available


  64. CANNIOTO RA, Hutson A, Dighe S, McCann W, et al
    Physical activity before, during and after chemotherapy for high-risk breast cancer: relationships with survival.
    J Natl Cancer Inst. 2020 Apr 2. pii: 5814214. doi: 10.1093.
    PubMed     Abstract available


  65. CHIARELLI AM, Blackmore KM, Mirea L, Done SJ, et al
    Annual vs Biennial Screening: Diagnostic Accuracy Among Concurrent Cohorts Within the Ontario Breast Screening Program.
    J Natl Cancer Inst. 2020;112:400-409.
    PubMed     Abstract available


    March 2020
  66. JEZEQUEL P, Patsouris A, Guette C, Juin PP, et al
    RE: Immune checkpoint profiles in luminal B breast cancer (Alliance).
    J Natl Cancer Inst. 2020 Mar 19. pii: 5810085. doi: 10.1093.
    PubMed    


  67. REINER AS, Robson ME, Mellemkjaer L, Tischkowitz M, et al
    Radiation treatment, ATM, BRCA1/2, and CHEK2*1100delC pathogenic variants, and risk of contralateral breast cancer.
    J Natl Cancer Inst. 2020 Mar 2. pii: 5771357. doi: 10.1093.
    PubMed     Abstract available


    February 2020
  68. YANG X, Song H, Leslie G, Engel C, et al
    Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D.
    J Natl Cancer Inst. 2020 Feb 28. pii: 5764125. doi: 10.1093.
    PubMed     Abstract available


  69. TERAS LR, Patel AV, Smith-Warner SA
    Re: Sustained weight loss and risk of breast cancer in women >/=50 years - Authors' Reply.
    J Natl Cancer Inst. 2020 Feb 26. pii: 5758264. doi: 10.1093.
    PubMed    


  70. FLEGAL KM
    Re: Sustained weight loss and risk of breast cancer in women >/=50 years: a pooled analysis of prospective data.
    J Natl Cancer Inst. 2020 Feb 26. pii: 5758265. doi: 10.1093.
    PubMed    


  71. HU C, Polley EC, Yadav S, Lilyquist J, et al
    The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort.
    J Natl Cancer Inst. 2020 Feb 24. pii: 5753953. doi: 10.1093.
    PubMed     Abstract available


  72. YAFFE MJ, Mainprize JG
    The Value of All-Cause Mortality as a Metric for Assessing Breast Cancer Screening.
    J Natl Cancer Inst. 2020 Feb 14. pii: 5736137. doi: 10.1093.
    PubMed     Abstract available


  73. HABEL LA, Buist DSM
    Re: Cancer Outcomes in DCIS Patients Without Locoregional Treatment.
    J Natl Cancer Inst. 2020;112:214-215.
    PubMed    


  74. CHIARELLI AM, Blackmore KM, Muradali D, Done SJ, et al
    Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program.
    J Natl Cancer Inst. 2020;112:136-144.
    PubMed     Abstract available


    January 2020
  75. ARTHUR RS, Wang T, Xue X, Kamensky V, et al
    Genetic factors, adherence to healthy lifestyle behavior, and risk of invasive breast cancer among women in the UK Biobank.
    J Natl Cancer Inst. 2020 Jan 3. pii: 5695712. doi: 10.1093.
    PubMed     Abstract available


    December 2019
  76. SEBUODEGARD S, Botteri E, Hofvind S
    Breast cancer mortality after implementation of organized population-based breast cancer screening in Norway.
    J Natl Cancer Inst. 2019 Dec 17. pii: 5678884. doi: 10.1093.
    PubMed     Abstract available


  77. TERAS LR, Patel AV, Wang M, Yaun SS, et al
    Sustained weight loss and risk of breast cancer in women >/=50 years: a pooled analysis of prospective data.
    J Natl Cancer Inst. 2019 Dec 13. pii: 5675519. doi: 10.1093.
    PubMed     Abstract available


    November 2019
  78. BRUFSKY A, Mathew A
    Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does It Matter?
    J Natl Cancer Inst. 2019 Nov 6. pii: 5613898. doi: 10.1093.
    PubMed    


    October 2019
  79. GRALOW JR, Barlow WE, Paterson AHG, Miao JL, et al
    Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307.
    J Natl Cancer Inst. 2019 Oct 31. pii: 5613900. doi: 10.1093.
    PubMed     Abstract available


  80. ANURAG M, Zhu M, Huang C, Vasaikar S, et al
    Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).
    J Natl Cancer Inst. 2019 Oct 30. pii: 5610076. doi: 10.1093.
    PubMed     Abstract available


  81. BARECHE Y, Buisseret L, Gruosso T, Girard E, et al
    Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach.
    J Natl Cancer Inst. 2019 Oct 29. pii: 5609116. doi: 10.1093.
    PubMed     Abstract available


  82. BRAUNSTEIN LZ, Riaz N
    Microenvironmental heterogeneity among triple negative breast cancer subtypes and the promise of precision medicine.
    J Natl Cancer Inst. 2019 Oct 29. pii: 5609117. doi: 10.1093.
    PubMed    


  83. HEY SP, Gyawali B, D'Andrea E, Kanagaraj M, et al
    A Systematic Review and Meta-analysis of Bevacizumab in First-line Metastatic Breast Cancer: Lessons for the Research and Regulatory Enterprises.
    J Natl Cancer Inst. 2019 Oct 25. pii: 5607300. doi: 10.1093.
    PubMed     Abstract available


  84. TORRES MA, Gogineni K, Howard DH
    Intensity-modulated radiation therapy in breast cancer patients following the release of a Choosing Wisely recommendation.
    J Natl Cancer Inst. 2019 Oct 24. pii: 5606721. doi: 10.1093.
    PubMed     Abstract available


  85. SMITH GL, Smith BD
    Sea Change: A Decade of IMRT for Treatment of Breast Cancer.
    J Natl Cancer Inst. 2019 Oct 24. pii: 5606720. doi: 10.1093.
    PubMed    


  86. RUDDY KJ, Herrin J, Sangaralingham L, Freedman RA, et al
    Follow-up care for breast cancer survivors.
    J Natl Cancer Inst. 2019 Oct 15. pii: 5587764. doi: 10.1093.
    PubMed     Abstract available


  87. FREEDMAN RA, Winer EP
    Adjuvant chemotherapy for older patients with breast cancer: When is the pain worth the gain?
    J Natl Cancer Inst. 2019 Oct 15. pii: 5573122. doi: 10.1093.
    PubMed    


  88. CHANDLER Y, Jayasekera J, Schechter C, Isaacs C, et al
    Simulation of Chemotherapy Effects in Older Breast Cancer Patients With High Recurrence Scores.
    J Natl Cancer Inst. 2019 Oct 15. pii: 5573123. doi: 10.1093.
    PubMed     Abstract available


  89. CHECK DK, Winn AN, Fergestrom N, Reeder-Hayes KE, et al
    Concurrent Opioid and Benzodiazepine Prescriptions among Older Women Diagnosed with Breast Cancer.
    J Natl Cancer Inst. 2019 Oct 12. pii: 5586329. doi: 10.1093.
    PubMed     Abstract available


  90. SPENCER JC, Rotter JS, Eberth JM, Zahnd WE, et al
    Employment changes following breast cancer diagnosis: the effects of race and place.
    J Natl Cancer Inst. 2019 Oct 10. pii: 5585013. doi: 10.1093.
    PubMed     Abstract available


  91. DEKKERS JF, Whittle JR, Vaillant F, Chen HR, et al
    Modeling breast cancer using CRISPR/Cas9-mediated engineering of human breast organoids.
    J Natl Cancer Inst. 2019 Oct 7. pii: 5582651. doi: 10.1093.
    PubMed     Abstract available


  92. MACINNIS RJ, Liao Y, Knight JA, Milne RL, et al
    Considerations when using breast cancer risk models for women with negative BRCA1/BRCA2 mutation results.
    J Natl Cancer Inst. 2019 Oct 4. pii: 5581413. doi: 10.1093.
    PubMed     Abstract available


    September 2019
  93. MCCARTHY AM, Guan Z, Welch M, Griffin ME, et al
    Performance of breast cancer risk assessment models in a large mammography cohort.
    J Natl Cancer Inst. 2019 Sep 26. pii: 5574009. doi: 10.1093.
    PubMed     Abstract available


  94. GAIL MH
    Choosing Breast Cancer Risk Models: Importance of Independent Validation.
    J Natl Cancer Inst. 2019 Sep 26. pii: 5574008. doi: 10.1093.
    PubMed    


  95. PALMER JR
    Polygenic risk scores for breast cancer risk prediction: Lessons learned and future opportunities.
    J Natl Cancer Inst. 2019 Sep 25. pii: 5573761. doi: 10.1093.
    PubMed    


  96. SHIEH Y, Fejerman L, Lott PC, Marker K, et al
    A polygenic risk score for breast cancer in U.S. Latinas and Latin-American women.
    J Natl Cancer Inst. 2019 Sep 25. pii: 5573760. doi: 10.1093.
    PubMed     Abstract available


  97. SUNG H, Rosenberg PS, Yang XR
    Re: Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians versus the US Population.
    J Natl Cancer Inst. 2019 Sep 23. pii: 5572664. doi: 10.1093.
    PubMed    


  98. LOWRY KP, Trentham-Dietz A, Schechter CB, Alagoz O, et al
    Long-term Outcomes and Cost-effectiveness of Breast Cancer Screening with Digital Breast Tomosynthesis in the United States.
    J Natl Cancer Inst. 2019 Sep 10. pii: 5567105. doi: 10.1093.
    PubMed     Abstract available


  99. FAHRMANN JF, Vykoukal J, Fleury A, Tripathi S, et al
    Association between plasma diacetylspermine and tumor spermine synthase with outcome in triple negative breast cancer.
    J Natl Cancer Inst. 2019 Sep 10. pii: 5567103. doi: 10.1093.
    PubMed     Abstract available


  100. SHIH YT, Shen Y
    Time to Consider a Personalized Approach to Incorporate Tomosynthesis into Routine Breast Cancer Screening.
    J Natl Cancer Inst. 2019 Sep 10. pii: 5567104. doi: 10.1093.
    PubMed    


  101. DEMB J, Abraham L, Miglioretti DL, Sprague BL, et al
    Screening mammography outcomes: risk of breast cancer and mortality by comorbidity score and age.
    J Natl Cancer Inst. 2019 Sep 6. pii: 5556084. doi: 10.1093.
    PubMed     Abstract available


    August 2019
  102. COMEN EA, Bowman RL, Selenica P, Kleppe M, et al
    Evaluating clonal hematopoiesis in tumor infiltrating leukocytes in breast cancer and secondary hematologic malignancies.
    J Natl Cancer Inst. 2019 Aug 27. pii: 5555367. doi: 10.1093.
    PubMed     Abstract available


  103. SPERLING AS, Ebert BL
    CHIPing away at breast cancer.
    J Natl Cancer Inst. 2019 Aug 27. pii: 5555366. doi: 10.1093.
    PubMed    


    July 2019
  104. AZAM S, Eriksson M, Sjolander A, Hellgren R, et al
    Mammographic Density Change and Risk of Breast Cancer.
    J Natl Cancer Inst. 2019 Jul 12. pii: 5531652. doi: 10.1093.
    PubMed     Abstract available


  105. BARLOW WE, Beaber EF, Geller BM, Kamineni A, et al
    Evaluating screening participation, follow-up and outcomes for breast, cervical and colorectal cancer in the PROSPR consortium.
    J Natl Cancer Inst. 2019 Jul 11. pii: 5530599. doi: 10.1093.
    PubMed     Abstract available


    June 2019
  106. SACCARELLI CR, Bitencourt AGV, Morris EA
    Breast cancer screening in high-risk women: is MRI alone enough?
    J Natl Cancer Inst. 2019 Jun 24. pii: 5522375. doi: 10.1093.
    PubMed    


  107. ROSSI PG, Paci E
    RE: Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
    J Natl Cancer Inst. 2019 Jun 19. pii: 5520439. doi: 10.1093.
    PubMed    


  108. GUI Y, Liu X, Chen X, Yang X, et al
    A network meta-analysis of surgical treatment in patients with early breast cancer.
    J Natl Cancer Inst. 2019 Jun 11. pii: 5514059. doi: 10.1093.
    PubMed     Abstract available


  109. DI COSIMO S, Torri V, Porcu L
    RE: Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
    J Natl Cancer Inst. 2019 Jun 11. pii: 5514057. doi: 10.1093.
    PubMed    


  110. CHOUDHURY PP, Wilcox AN, Brook MN, Zhang Y, et al
    Comparative validation of breast cancer risk prediction models and projections for future risk stratification.
    J Natl Cancer Inst. 2019 Jun 4. pii: 5511406. doi: 10.1093.
    PubMed     Abstract available


    May 2019
  111. YANG Y, Wu L, Shu XO, Cai Q, et al
    Genetically predicted levels of DNA methylation biomarkers and breast cancer risk: data from 228,951 women of European descent.
    J Natl Cancer Inst. 2019 May 29. pii: 5505447. doi: 10.1093.
    PubMed     Abstract available


  112. SU Y, Huang J, Wang S, Unger JM, et al
    The Effects of Ganglioside-Monosialic Acid in Taxane-induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial.
    J Natl Cancer Inst. 2019 May 15. pii: 5489913. doi: 10.1093.
    PubMed     Abstract available


  113. GOMEZ SL, Yao S, Kushi LH, Kurian AW, et al
    Is breast cancer in Asian and Asian American women a different disease?
    J Natl Cancer Inst. 2019 May 15. pii: 5489912. doi: 10.1093.
    PubMed    


  114. LIN CH, Yap YS, Lee KH, Im SA, et al
    Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians versus the US Population.
    J Natl Cancer Inst. 2019 May 15. pii: 5489914. doi: 10.1093.
    PubMed     Abstract available


  115. TESSIER L, Furzer J, Hodgson D, Cotton C, et al
    Cost-Utility of Early Breast Cancer Surveillance in Survivors of Thoracic Radiation-Treated Adolescent Hodgkin's Lymphoma.
    J Natl Cancer Inst. 2019 May 9. pii: 5485250. doi: 10.1093.
    PubMed     Abstract available


    April 2019
  116. PRAT A, Pascual T, De Angelis C, Gutierrez C, et al
    HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade.
    J Natl Cancer Inst. 2019 Apr 30. pii: 5475264. doi: 10.1093.
    PubMed     Abstract available


  117. MARIOTTO A, Jayasekerea J, Petkov V, Schechter CB, et al
    Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.
    J Natl Cancer Inst. 2019 Apr 24. pii: 5475265. doi: 10.1093.
    PubMed     Abstract available


  118. MUKHOPADHYAY UK, Oturkar CC, Adams C, Wickramasekera N, et al
    TP53 Status as a Determinant of Pro- versus Anti-tumorigenic Effects of Estrogen Receptor-beta in Breast Cancer.
    J Natl Cancer Inst. 2019 Apr 16. pii: 5452444. doi: 10.1093.
    PubMed     Abstract available


  119. BADVE S, Gokmen-Polar Y
    TP53 Status and Estrogen Receptor-beta in Triple Negative Breast Cancer: Company matters.
    J Natl Cancer Inst. 2019 Apr 16. pii: 5452445. doi: 10.1093.
    PubMed    


  120. XU Z, Sandler DP, Taylor JA
    Blood DNA methylation and breast cancer: A prospective case-cohort analysis in the Sister Study.
    J Natl Cancer Inst. 2019 Apr 15. pii: 5466458. doi: 10.1093.
    PubMed     Abstract available


  121. LI N, McInerny S, Zethoven M, Cheasley D, et al
    Combined tumor sequencing and case/control analyses of RAD51C in breast cancer.
    J Natl Cancer Inst. 2019 Apr 5. pii: 5428180. doi: 10.1093.
    PubMed     Abstract available


    March 2019
  122. KIM RS, Song N, Gavin PG, Salgado R, et al
    Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer.
    J Natl Cancer Inst. 2019 Mar 19. pii: 5393262. doi: 10.1093.
    PubMed     Abstract available


  123. RODRIGUEZ-RUIZ A, Lang K, Gubern-Merida A, Broeders M, et al
    Stand-Alone Artificial Intelligence for Breast Cancer Detection in Mammography: Comparison With 101 Radiologists.
    J Natl Cancer Inst. 2019 Mar 5. pii: 5307077. doi: 10.1093.
    PubMed     Abstract available


    February 2019
  124. KRESOVICH JK, Xu Z, O'Brien KM, Weinberg CR, et al
    Methylation-based biological age and breast cancer risk.
    J Natl Cancer Inst. 2019 Feb 22. pii: 5341521. doi: 10.1093.
    PubMed     Abstract available


  125. NGUYEN B, Veys I, Leduc S, Bareche Y, et al
    Genomic, transcriptomic, epigenetic, and immune profiling of mucinous breast cancer.
    J Natl Cancer Inst. 2019 Feb 21. pii: 5355042. doi: 10.1093.
    PubMed     Abstract available


  126. COHN BA, Cirillo PM, Terry MB
    DDT and Breast Cancer: Prospective Study of Induction Time and Susceptibility Windows.
    J Natl Cancer Inst. 2019 Feb 13. pii: 5299924. doi: 10.1093.
    PubMed     Abstract available


  127. LEE CI, Elmore JG
    Artificial Intelligence for Breast Cancer Imaging: The New Frontier?
    J Natl Cancer Inst. 2019 Feb 5. pii: 5307046. doi: 10.1093.
    PubMed    


    January 2019
  128. ABDEL-QADIR H, Thavendiranathan P, Austin PC, Lee DS, et al
    The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study.
    J Natl Cancer Inst. 2019 Jan 31. pii: 5304781. doi: 10.1093.
    PubMed     Abstract available


  129. LENIHAN DJ
    Cardiac Disease After Breast Cancer Treatment: Make Sure to Check Our Blind Spot!
    J Natl Cancer Inst. 2019 Jan 31. pii: 5304780. doi: 10.1093.
    PubMed    


  130. KRAMER I, Schaapveld M, Oldenburg HSA, Sonke GS, et al
    The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype.
    J Natl Cancer Inst. 2019 Jan 30. pii: 5304371. doi: 10.1093.
    PubMed     Abstract available


  131. CHEUNG KJ, Davidson NE
    Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era.
    J Natl Cancer Inst. 2019 Jan 28. pii: 5303805. doi: 10.1093.
    PubMed    


  132. PAREJA F, Lee JY, Brown DN, Piscuoglio S, et al
    The Genomic Landscape of Mucinous Breast Cancer.
    J Natl Cancer Inst. 2019 Jan 11. pii: 5288408. doi: 10.1093.
    PubMed     Abstract available


  133. REEVES KW, Santana MD, Manson JE, Hankinson SE, et al
    Urinary Phthalate Biomarker Concentrations and Postmenopausal Breast Cancer Risk.
    J Natl Cancer Inst. 2019 Jan 10. pii: 5284913. doi: 10.1093.
    PubMed     Abstract available


  134. HUILLARD O, Le Strat Y, Dubertret C, Goldwasser F, et al
    RE: Associations between breast cancer survivorship and adverse mental health outcomes: a systematic review.
    J Natl Cancer Inst. 2019 Jan 10. pii: 5284914. doi: 10.1093.
    PubMed    


  135. SPRAGUE BL, Kerlikowske K, Bowles EJA, Rauscher GH, et al
    Trends in Clinical Breast Density Assessment From the Breast Cancer Surveillance Consortium.
    J Natl Cancer Inst. 2019 Jan 8. pii: 5280767. doi: 10.1093.
    PubMed     Abstract available


    November 2018
  136. TERRY MB, Daly MB, Phillips KA, Ma X, et al
    Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk.
    J Natl Cancer Inst. 2018 Nov 28. pii: 5212812. doi: 10.1093.
    PubMed     Abstract available


  137. HATEM E, Azzi S, El Banna N, He T, et al
    Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2018 Nov 20. pii: 5193772. doi: 10.1093.
    PubMed     Abstract available


  138. HATEM E, Azzi S, El Banna N, He T, et al
    Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2018 Nov 20. pii: 5342932. doi: 10.1093.
    PubMed     Abstract available


  139. KENSLER KH, Poole EM, Heng YJ, Collins LC, et al
    Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies.
    J Natl Cancer Inst. 2018 Nov 15. pii: 5184399. doi: 10.1093.
    PubMed     Abstract available


  140. CARREIRA H, Williams R, Muller M, Harewood R, et al
    Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review.
    J Natl Cancer Inst. 2018 Nov 7. pii: 5164282. doi: 10.1093.
    PubMed     Abstract available


    October 2018
  141. QIAN F, Wang S, Mitchell J, McGuffog L, et al
    Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study.
    J Natl Cancer Inst. 2018 Oct 12. pii: 5128773. doi: 10.1093.
    PubMed     Abstract available


  142. TRAPP E, Janni W, Schindlbeck C, Juckstock J, et al
    Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
    J Natl Cancer Inst. 2018 Oct 11. pii: 5127124. doi: 10.1093.
    PubMed     Abstract available


  143. SPARANO JA, Henry NL
    Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?
    J Natl Cancer Inst. 2018 Oct 11. pii: 5127122. doi: 10.1093.
    PubMed    


  144. DESANTIS CE, Jemal A
    Re: Black-White Breast Cancer Incidence Trends: Effects of Ethnicity.
    J Natl Cancer Inst. 2018 Oct 10. pii: 5126439. doi: 10.1093.
    PubMed    


    September 2018
  145. LEE JY, Joo HS, Choi HJ, Jin S, et al
    Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.
    J Natl Cancer Inst. 2018 Sep 27. pii: 5103386. doi: 10.1093.
    PubMed     Abstract available


  146. HELZLSOUER KJ
    Can Less Be More for Individuals With Low-Risk Breast Cancer?
    J Natl Cancer Inst. 2018 Sep 18. pii: 5101448. doi: 10.1093.
    PubMed    


  147. JAYASEKERA J, Schechter CB, Sparano JA, Jagsi R, et al
    Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer.
    J Natl Cancer Inst. 2018 Sep 18. pii: 5101449. doi: 10.1093.
    PubMed     Abstract available


    August 2018
  148. MARINOVICH ML, Hunter KE, Macaskill P, Houssami N, et al
    Breast Cancer Screening Using Tomosynthesis or Mammography: A Meta-analysis of Cancer Detection and Recall.
    J Natl Cancer Inst. 2018 Aug 9. pii: 5068658. doi: 10.1093.
    PubMed     Abstract available


  149. SHIMELIS H, LaDuca H, Hu C, Hart SN, et al
    Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing.
    J Natl Cancer Inst. 2018 Aug 7. pii: 5062996. doi: 10.1093.
    PubMed     Abstract available


    July 2018
  150. DIERAS V, Rugo HS, Schnell P, Gelmon K, et al
    Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
    J Natl Cancer Inst. 2018 Jul 18. pii: 5055701. doi: 10.1093.
    PubMed     Abstract available



  151. Corrigendum to "Cost and Complications of Local Therapies for Early-Stage Breast Cancer".
    J Natl Cancer Inst. 2018 Jul 16. pii: 5054617. doi: 10.1093.
    PubMed    


  152. LU DL, Le Cornet C, Sookthai D, Johnson TS, et al
    Circulating 27-Hydroxycholesterol and Breast Cancer Risk: Results From the EPIC-Heidelberg Cohort.
    J Natl Cancer Inst. 2018 Jul 16. pii: 5054612. doi: 10.1093.
    PubMed     Abstract available


  153. DAVIS LYNN BC, Rosenberg PS, Anderson WF, Gierach GL, et al
    Black-White Breast Cancer Incidence Trends: Effects of Ethnicity.
    J Natl Cancer Inst. 2018 Jul 5. pii: 5049141. doi: 10.1093.
    PubMed     Abstract available


    June 2018
  154. LAMBERTINI M, Campbell C, Bines J, Korde LA, et al
    Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.
    J Natl Cancer Inst. 2018 Jun 5. pii: 5033460. doi: 10.1093.
    PubMed     Abstract available


  155. CATHCART-RAKE E, Gast KC, Ruddy KJ
    What Can We Learn From Menstrual Patterns After Treatment for HER2-Positive Breast Cancer?
    J Natl Cancer Inst. 2018 Jun 5. pii: 5033462. doi: 10.1093.
    PubMed    



  156. Corrigendum to "Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer".
    J Natl Cancer Inst. 2018;110:684.
    PubMed    


    May 2018
  157. PATTERSON RE, Marinac CR, Sears DD, Kerr J, et al
    The Effects of Metformin and Weight Loss on Biomarkers Associated With Breast Cancer Outcomes.
    J Natl Cancer Inst. 2018 May 18. pii: 4999668. doi: 10.1093.
    PubMed     Abstract available


  158. LOHMANN AE, Pimentel I, Goodwin PJ
    Novel Insights Into the Impact of Lifestyle-Based Weight Loss and Metformin on Obesity-Associated Biomarkers in Breast Cancer.
    J Natl Cancer Inst. 2018 May 18. pii: 4999672. doi: 10.1093.
    PubMed    


    April 2018
  159. DESMEDT C, Demicheli R, Fornili M, Bachir I, et al
    Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index.
    J Natl Cancer Inst. 2018 Apr 30. pii: 4975381. doi: 10.1093.
    PubMed     Abstract available


  160. JAYASEKERA J, Li Y, Schechter CB, Jagsi R, et al
    Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer.
    J Natl Cancer Inst. 2018 Apr 28. pii: 4990602. doi: 10.1093.
    PubMed     Abstract available


  161. BIDARD FC, Michiels S, Riethdorf S, Mueller V, et al
    Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.
    J Natl Cancer Inst. 2018 Apr 12. pii: 4969338. doi: 10.1093.
    PubMed     Abstract available


  162. CHOI HJ, Joo HS, Won HY, Min KW, et al
    Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


  163. VERMA V, Simone CB 2nd, Mishra MV
    Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


    March 2018
  164. MATIKAS A, Foukakis T, Bergh J
    RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018 Mar 29. pii: 4956469. doi: 10.1093.
    PubMed    


  165. HAWK E, Maresso KC, Brown P
    NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question.
    J Natl Cancer Inst. 2018 Mar 15. pii: 4938606. doi: 10.1093.
    PubMed    


  166. RITZWOLLER DP, Hassett MJ, Uno H, Cronin AM, et al
    Development, Validation, and Dissemination of a Breast Cancer Recurrence Detection and Timing Informatics Algorithm.
    J Natl Cancer Inst. 2018;110:273-281.
    PubMed     Abstract available


    February 2018
  167. GAIL MH, Pfeiffer RM
    Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening.
    J Natl Cancer Inst. 2018 Feb 27. pii: 4912416. doi: 10.1093.
    PubMed     Abstract available


  168. ZACHARIAE R, Amidi A, Damholdt MF, Clausen CDR, et al
    Internet-Delivered Cognitive-Behavioral Therapy for Insomnia in Breast Cancer Survivors: A Randomized Controlled Trial.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881759. doi: 10.1093.
    PubMed     Abstract available


  169. OESTERREICH S, Lucas PC, McAuliffe PF, Bruno TC, et al
    Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881762. doi: 10.1093.
    PubMed    


  170. DESMEDT C, Salgado R, Fornili M, Pruneri G, et al
    Immune Infiltration in Invasive Lobular Breast Cancer.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881757. doi: 10.1093.
    PubMed     Abstract available


  171. IRWIN MR
    Innovation in the Treatment of Insomnia in Breast Cancer Survivors.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881761. doi: 10.1093.
    PubMed    


  172. BROWN J, Rathbone E, Hinsley S, Gregory W, et al
    Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.
    J Natl Cancer Inst. 2018 Feb 7. pii: 4842040. doi: 10.1093.
    PubMed     Abstract available


  173. BANDOS H, Melnikow J, Rivera DR, Swain SM, et al
    Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


  174. RIVERA DR, Ganz PA, Weyrich MS, Bandos H, et al
    Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


  175. JAGSI R, Momoh AO, Qi J, Hamill JB, et al
    Impact of Radiotherapy on Complications and Patient-Reported Outcomes After Breast Reconstruction.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


    January 2018
  176. LINDSTROM LS, Yau C, Czene K, Thompson CK, et al
    Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
    J Natl Cancer Inst. 2018 Jan 19. pii: 4780395. doi: 10.1093.
    PubMed     Abstract available


  177. OZTURK TOPCU T, Jerzak KJ, Warner E
    RE: Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
    J Natl Cancer Inst. 2018 Jan 10. pii: 4797407. doi: 10.1093.
    PubMed    


  178. LASKY-SU JA, Zeleznik OA, Eliassen AH
    Using Metabolomics to Explore the Role of Postmenopausal Adiposity in Breast Cancer Risk.
    J Natl Cancer Inst. 2018 Jan 9. pii: 4795354. doi: 10.1093.
    PubMed    


  179. MOORE SC, Playdon MC, Sampson JN, Hoover RN, et al
    A Metabolomics Analysis of Body Mass Index and Postmenopausal Breast Cancer Risk.
    J Natl Cancer Inst. 2018 Jan 9. pii: 4795343. doi: 10.1093.
    PubMed     Abstract available


  180. SCHRIJVER WAME, Suijkerbuijk KPM, van Gils CH, van der Wall E, et al
    Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018 Jan 5. pii: 4791841. doi: 10.1093.
    PubMed     Abstract available


  181. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


  182. GOLDVASER H, Barnes TA, Seruga B, Cescon DW, et al
    Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


  183. JOHNSON SB, Park HS, Gross CP, Yu JB, et al
    Use of Alternative Medicine for Cancer and Its Impact on Survival.
    J Natl Cancer Inst. 2018;110.
    PubMed     Abstract available


    December 2017
  184. POORVU PD, Winer EP
    Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway.
    J Natl Cancer Inst. 2017 Dec 11. pii: 4718502. doi: 10.1093.
    PubMed    


  185. KURIAN AW, Bondarenko I, Jagsi R, Friese CR, et al
    Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2017 Dec 11. pii: 4718501. doi: 10.1093.
    PubMed     Abstract available


  186. GLUZ O, Nitz U, Liedtke C, Christgen M, et al
    Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
    J Natl Cancer Inst. 2017 Dec 8. pii: 4698155. doi: 10.1093.
    PubMed     Abstract available


    November 2017
  187. BELKACEMI Y, Kuten A
    RE: Regional Nodal Irradiation After Breast-Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
    J Natl Cancer Inst. 2017 Nov 21. pii: 4645256. doi: 10.1093.
    PubMed    


  188. MEIER M, Orr N
    Genetic Determinants of Breast Cancer Risk in Childhood Cancer Survivors.
    J Natl Cancer Inst. 2017;109.
    PubMed    


  189. MORTON LM, Sampson JN, Armstrong GT, Chen TH, et al
    Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available


  190. DESHMUKH AA, Shirvani SM, Lal L, Swint JM, et al
    Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available


  191. SCHWARZ LJ, Hutchinson KE, Rexer BN, Estrada MV, et al
    An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    J Natl Cancer Inst. 2017;109.
    PubMed     Abstract available


    October 2017
  192. LAMBERTINI M, Kroman N, Ameye L, Cordoba O, et al
    Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
    J Natl Cancer Inst. 2017 Oct 26. doi: 10.1093.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: